Heat Biologics, a Miami Beach, FL-based clinical-stage immunotherapy company focused on developing drugs to combat a wide range of diseases, has completed an initial funding round of undisclosed amount.
The investment was led by Brightline Ventures.
The funds will be used to accelerate ongoing clinical trials of Heat’s therapeutic vaccines to treat Non Small Cell Lung Cancer (NSCLC). The capital will also enable the company to prepare two new products to enter clinical trials in the first quarter of 2011.
Launched in 2008 by Seed-One Ventures, Heat Biologics has developed the HS-System, a proprietary live cell vaccine that stimulates the immune system and enables it to combat a variety of cancers, viral infections and other diseases.
Heat’s HS-L1 therapeutic vaccine for NSCLC is currently being tested in a Phase I/II clinical trial involving 36 patients. Results are expected in early 2011.
In addition to cancer, the HS-System is currently in advanced primate studies to test its utility in viral applications.